KOSDAQIT & Software071200

INFINITT Healthcare

₩10,790▲ 3.55%2026-11-18 close
Market Cap
₩263.2B
Turnover
₩400M
Volume
40K
Shares out.
24.4M
PER
8.1×
PBR
1.3×
EPS
₩1,382
Dividend Yield
—

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Prices as of the 2026-11-18 close

01

Report overview

Imaging software leader with mixed earnings trend

INFINITT Healthcare, a leader in domestic PACS, raised operating profit 84.1% in 2025, but its controlling-shareholder net income swung to a KRW 16.9 billion net loss in Q3 2026, leaving earnings durability as the central open question.

  1. 1

    Core revenue comes from PACS and 3D medical imaging software, and the company is described as holding high shares in the domestic top-tier and general hospital markets.

  2. 2

    Revenue reached KRW 102.4 billion in 2025, up 6.9% year on year, and operating profit reached KRW 14.2 billion, up 84.1%, for a 13.9% operating margin.

  3. 3

    Q3 2026 operating profit stayed positive at KRW 4.18 billion, while controlling-shareholder net loss was KRW 16.9 billion. The reason for the divergence must be traced to non-operating items and taxes.

  4. 4

    H1 2026 revenue reached KRW 57.6 billion and operating profit KRW 14.4 billion, both up year on year, and European sales grew 47.5%, the fastest among overseas regions.

  5. 5

    The next periodic report is the 2026 annual report. Until then, the continued quarterly decline in operating profit and the cause of the controlling-shareholder net loss are the key points to watch.

02

Business structure

INFINITT Healthcare is focused on medical imaging information solutions, and its main revenue comes from selling PACS and 3D medical imaging software. An equity information site classifies its revenue mix as 100% software, with radiology and cardiology PACS cited as flagship products.

The company has long held the top position in the domestic PACS market, and on the basis of the Health Insurance Review and Assessment Service's list of hospitals, it is described as holding 75% of the top-tier hospital market and 70% of the general hospital market.

Its customers are mostly hospitals, and because the products store imaging data and provide reading environments, maintenance and service contracts tend to follow after installation. Service revenue reached KRW 36.8 billion in H1 2026, or 63.8% of total revenue, which shows this structure in the reported numbers.

Overseas sales are also growing, with European revenue rising 47.5% to KRW 6.8 billion in H1 2026 from KRW 4.6 billion a year earlier, the fastest growth among overseas regions. Reports say the product scope is widening into North American PACS with AI integration and digital pathology.

According to the company's profile, it has repeatedly been selected as a category leader in a global PACS evaluation. The competitive picture rests on a high share among large domestic hospitals, so growth depends on retaining existing customers and expanding overseas and into AI.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩22.1B-₩1.5B−7.0%
2025Q4₩30B₩11.6B38.6%
2026Q1₩32.1B₩9.5B29.4%
2026Q2₩25.5B₩4.9B19.3%
2026Q3₩25.9B₩4.2B16.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩88.3B₩7.7B₩100M8.7%0.1%30.2%
2023₩89.4B₩3.1B₩16.5B3.5%12.5%31.0%
2024₩95.8B₩7.7B₩37.8B8.1%22.4%29.4%
2025₩102.4B₩14.2B₩26.4B13.9%13.8%27.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual revenue rose from KRW 88.3 billion in 2022 to KRW 89.4 billion in 2023 (up 1.3%), KRW 95.8 billion in 2024 (up 7.1%), and KRW 102.4 billion in 2025 (up 6.9%). Revenue has increased for three consecutive years from 2023 through 2025, and 2025 was the largest year of 2022 to 2025.

Operating profit fell from KRW 7.69 billion in 2022 to KRW 3.09 billion in 2023 (down 59.9%), the smallest year of the period, then rose to KRW 7.72 billion in 2024 (up 150.2%) and KRW 14.2 billion in 2025 (up 84.1%), growing two consecutive years from 2024 through 2025.

The operating margin was 8.7% in 2022, 3.5% in 2023, 8.1% in 2024 and 13.9% in 2025, the highest of the period. Controlling-shareholder net income rose from KRW 132 million in 2022 to KRW 16.5 billion in 2023 (up 12,411.0%) and KRW 37.8 billion in 2024 (up 129.6%), then fell to KRW 26.4 billion in 2025 (down 30.1%).

The small 2022 base explains why the growth rates look so large. In 2025 operating profit rose while controlling-shareholder net income fell, so operating performance and bottom-line results moved in opposite directions.

One analysis of the nine-month 2025 disclosure said profitability was constrained by a smaller reversal of inventory valuation losses and higher one-off costs.

Quarterly, the company moved from an operating loss of KRW 1.54 billion and revenue of KRW 22.1 billion in Q3 2025 to operating profit of KRW 11.6 billion and revenue of KRW 30 billion in Q4 2025.

Operating profit then declined for three consecutive quarters, to KRW 9.47 billion in Q1 2026, KRW 4.93 billion in Q2 and KRW 4.18 billion in Q3. Q3 2026 revenue was KRW 25.9 billion, up 17.4% year on year, but controlling-shareholder net income swung from KRW 25.2 billion in Q2 to a KRW 16.9 billion net loss in Q3.

Controlling-shareholder net income for the latest four quarters totals KRW 33.7 billion. In H1 2026, the cost of revenue ratio fell from 38.6% to 32.4% and selling and administrative expenses declined, which lifted operating profit sharply.

05

Industry analysis

Demand for medical imaging software continues alongside the expansion of digital clinical infrastructure in hospitals. One equity information site cited rising demand for medical software and sustained demand for patient monitoring and data management as the background to the earnings recovery.

In the domestic market the company is described as holding high shares among both top-tier and general hospitals, so revenue builds more from maintaining and upgrading existing customers than from competing for new orders.

This structure produces stable service revenue, but with domestic share already high, room for top-line growth tends to shift toward overseas markets and new products.

Since the operating profit trough in 2023, results have been in a recovery phase through 2024 and 2025, and revenue and operating profit both rose in H1 2026. In cycle terms, demand looks closer to a gradual pattern driven by hospital IT budgets and policy changes than to an equipment investment cycle.

That pattern carries the limitation that order timing can slip with hospital investment capacity and changes in healthcare policy. Overseas, PACS and AI-linked products are becoming the competitive focus in advanced markets such as North America and Europe, and European revenue grew fastest among overseas regions.

The competitive position will depend on whether a strong domestic share translates into a larger overseas share.

06

Outlook

Three growth axes are confirmed in the company's disclosures and reports. The first is overseas markets: in its Q1 2026 results commentary, expansion overseas and new products were cited as drivers, and European revenue rose 47.5% year on year in H1 2026.

The second is new products and AI, with reports saying the Smart Endo product has entered clinical settings and that the AI business is being strengthened. The third is product linkage, with North American PACS integrated with AI and expansion into digital pathology mentioned.

In H1 2026, expanded maintenance service contracts and cost efficiency were cited as drivers of operating profit improvement, and revenue for the same period rose 12.6% year on year. On shareholder returns, quarterly dividends run alongside the year-end dividend in the disclosure listings.

Still, Q3 2026 operating profit sits on the tail of three consecutive quarterly declines, and until the cause of the controlling-shareholder net loss is confirmed in a periodic report, the direction of earnings cannot be stated with confidence.

The next checkpoints are how quickly overseas revenue grows in share and whether AI-related products convert into revenue. The 2026 annual preliminary results expected in early 2027 and the 2026 annual report will show how the quarterly trend resolves at full-year level.

07

Valuation

PER
8.1×
PBR
1.3×
ROE
16.8%
EPS
₩1,382
BPS
₩8,718
Dividend per share
—

Valuation has to be read on both an earnings basis and a net asset basis. Controlling-shareholder net income, the denominator in earnings multiples, fell from KRW 37.8 billion in 2024 to KRW 26.4 billion in 2025 and turned into a net loss in Q3 2026, which makes earnings-based multiples harder to interpret.

The latest four quarters still total KRW 33.7 billion, and an earnings base this uneven feeds directly into the multiples. On a net asset basis, the price-to-book ratio is above 1x, which means the shares trade at a premium to net asset value.

A debt ratio of 27.8% at end-2025 and total equity of KRW 194.7 billion reduce the balance-sheet burden on that reading. Paying quarterly dividends can partly cushion earnings swings, but the dividend size moves with earnings.

Because earnings recovered after Q4 2025 and then swung to a loss in Q3 2026, the level at which the earnings baseline settles in the next periodic report is the starting point for interpreting the multiples.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Recurring revenue on a high domestic share

The company is described as holding 75% of the top-tier hospital market and 70% of the general hospital market. Service revenue reached KRW 36.8 billion in H1 2026, or 63.8% of total revenue, which supports a maintenance-driven revenue base. H1 2026 revenue rose 12.6% year on year.

Broader revenue base from overseas and new products

European revenue reached KRW 6.8 billion in H1 2026, up 47.5% from KRW 4.6 billion a year earlier, the fastest growth among overseas regions. North American PACS with AI integration and expansion into digital pathology have been reported. A larger overseas share creates a path beyond the limits of the domestic market.

Earnings recovery and financial capacity

The operating margin recovered from 3.5% in 2023 to 13.9% in 2025. In H1 2026 the cost of revenue ratio fell from 38.6% to 32.4%, and selling and administrative expenses declined. The debt ratio was 27.8% at end-2025, and total equity stood at KRW 194.7 billion.

09

Bear factors

Controlling-shareholder net loss in Q3

Controlling-shareholder net loss in Q3 2026 was KRW 16.9 billion, ending the profitable run that began in Q4 2025. Operating profit stayed positive at KRW 4.18 billion over the same period, so operating and bottom-line results moved in different directions. The cause cannot be pinned down until it appears in a periodic report.

Three straight quarters of lower operating profit

Operating profit peaked at KRW 11.6 billion in Q4 2025 and then fell for three consecutive quarters, to KRW 9.47 billion in Q1 2026, KRW 4.93 billion in Q2 and KRW 4.18 billion in Q3. Q3 operating profit fell 15.1% from the previous quarter. It remains well below the peak level.

Earnings volatility and one-off factors

Controlling-shareholder net income fell 30.1% from KRW 37.8 billion in 2024 to KRW 26.4 billion in 2025. The latest four quarters total KRW 33.7 billion, but the quarterly figures vary widely, so a single quarter can change the trend.

The nine-month 2025 disclosure analysis cited a smaller inventory valuation reversal and higher one-off costs as limits on profitability.

10

Risk factors

Earnings volatility and one-off items

In the nine months of 2025, inventory valuation reversals shrank and one-off costs rose. Operating profit rose 84.1% in 2025 while controlling-shareholder net income fell 30.1%, which suggests non-operating items may have grown in weight. Whether the Q3 2026 net loss was one-off or recurring must be confirmed in the periodic report.

Governance and litigation

A ruling confirming the invalidity of a resolution from an extraordinary shareholders' meeting tied to a June 23, 2025 meeting appears in the disclosures. The ruling outcome, the company's response and whether costs have been recognized are matters for later disclosures. Governance issues can affect shareholder confidence separately from earnings.

Overseas expansion and dependence on healthcare policy

European revenue is growing, but country-level regulation and certification procedures can delay when results show up. Domestic revenue depends on hospital investment capacity and healthcare policy, which can shift order timing. Both axes appear as quarterly swings, so quarterly revenue has to be read together with them.

11

What to watch next

  1. Early March 2027 (expected)

    2026 annual preliminary results. The 2025 preliminary results were disclosed electronically on March 13, 2026. How the quarterly decline in operating profit resolves on a full-year basis is the key point.

  2. By end-March 2027

    Deadline for submitting the 2026 annual report. This is where the detailed cause of the KRW 16.9 billion controlling-shareholder net loss should be confirmed and whether periodic report figures match the quarterly disclosures.

  3. Around the 2027 first-half shareholders' meeting

    Whether and how much of the 2026 fiscal year-end dividend is confirmed, and how earnings swings are reflected in the dividend policy.

  4. Mid-May 2027 (expected)

    Q1 2027 results. The Q1 2026 release came on May 14. This is where continuity in overseas revenue share and operating profit should be checked.

  5. Mid-August 2027 (expected)

    Q2 2027 results. The Q2 2026 release came on August 14. Whether controlling-shareholder net income recovers from the loss zone is the checkpoint.

12

Overall view

INFINITT Healthcare is a medical imaging software company with a high share of the domestic PACS market, and its service revenue, 63.8% of the total in H1 2026, gives it a recurring revenue base.

Revenue has grown for three consecutive years from 2023 through 2025, and the 13.9% operating margin in 2025 was the highest of 2022 to 2025. The debt ratio was 27.8% at end-2025, so the balance sheet is not heavily leveraged.

Earnings direction is mixed, however, with controlling-shareholder net income declining in 2025 and turning into a net loss in Q3 2026.

Operating profit has fallen for three consecutive quarters since peaking in Q4 2025, and the detailed cause of the KRW 16.9 billion Q3 net loss has to be confirmed in the periodic report.

Overseas expansion and AI and new products are growth drivers, but with domestic share already high, room for top-line growth tends to shift overseas.

The next checkpoints are the 2026 annual preliminary results expected in early 2027 and the 2026 annual report, and the key question is where the operating margin and controlling-shareholder net income settle.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. alphasquare.co.kr
  2. ssl.pstatic.net
  3. thevc.kr
  4. comp.fnguide.com
  5. medipana.com
  6. jobkorea.co.kr
  7. comp.fnguide.com
  8. jobplanet.co.kr
  9. saramin.co.kr
  10. comp.fnguide.com
  11. comp.wisereport.co.kr
  12. investing.com
  13. investing.com
  14. goinsider.kr
  15. datatooza.com
  16. cdn.fnguide.com
  17. comp.fnguide.com
  18. comp.fnguide.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis